A board and advisory bench with direct operating history at AbbVie, Bayer and Synairgen — and a scientific team that has been training on GPCRs since 2017.
Each of these people has sat on the other side of the table from Antiverse's target customer. Their credential is the risk signal — so it is stated, not implied.
Two decades evaluating and funding biotech assets on behalf of a top-five pharma. He has run the diligence process that Antiverse's partners will run.
Led biologics at Bayer. Knows precisely which targets large pharma abandons, and why — which is the list Antiverse works from.
Three decades of operating and exit experience across the pharmaceutical sector.
Former Chief Scientific Officer at Synairgen, with deep respiratory and translational science experience.
Business development leadership at one of the earliest AI-native drug discovery companies.
Machine learning, structural biology, molecular biology and assay development — in one building, working the same loop.
Not a sales team. The founders and the scientists.